Vaccination with intestinal tract antigens does not induce protective immunity in a permissive model of filariasis by Morris, C. Paul et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Uniformed Services University of the Health
Sciences U.S. Department of Defense
2013
Vaccination with intestinal tract antigens does not
induce protective immunity in a permissive model
of filariasis
C. Paul Morris
F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, National Institute of Allergy and
Infectious Disease, National Institutes of Health,
Marina N. Torrero
F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences
David Larson
F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences
Holly Evans
F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences
Yinghui Shi
F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/usuhs
This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Uniformed Services University of the Health Sciences by an authorized administrator of DigitalCommons@University
of Nebraska - Lincoln.
Morris, C. Paul; Torrero, Marina N.; Larson, David; Evans, Holly; Shi, Yinghui; Cox, Rachel T.; and Mitre, Edward, "Vaccination with
intestinal tract antigens does not induce protective immunity in a permissive model of filariasis" (2013). Uniformed Services University
of the Health Sciences. 140.
http://digitalcommons.unl.edu/usuhs/140
Authors
C. Paul Morris, Marina N. Torrero, David Larson, Holly Evans, Yinghui Shi, Rachel T. Cox, and Edward Mitre
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/usuhs/140
Vaccination with intestinal tract antigens does not induce protective
immunity in a permissive model of filariasis
C. Paul Morris a,c, Marina N. Torrero a, David Larson a, Holly Evans a, Yinghui Shi a, Rachel T. Cox b,
Edward Mitre a,⇑
aDepartment of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20852, USA
bDepartment of Biochemistry, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20852, USA
cNational Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
h i g h l i g h t s
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 Mice vaccinated with GutAg are not
protected from challenge infection.
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a b s t r a c t
Antigens obtained from the intestinal tract of filarial nematodes have been proposed as potential safe and
effective vaccine candidates. Because they may be ‘hidden’ from the immune response during natural
infection, yet accessible by antibodies induced by vaccination, intestinal antigens may have a low poten-
tial for eliciting allergic responses when vaccinating previously infected individuals. Despite prior prom-
ising data, vaccination with intestinal antigens has yet to be tested in a permissive model of filariasis. In
this study we investigated the efficacy of vaccination with filarial intestinal antigens in the permissive
Litomosoides sigmodontis BALB/c model of filariasis, and we evaluated the extent to which these antigens
are recognized by the immune system during and after infection. Infected BALB/c mice developed lower
IgG antibody responses to soluble intestinal antigens (GutAg) than to soluble antigens of whole worms
(LsAg). Similarly, GutAg induced less proliferation and less production of IL-4 and IFNc from splenocytes
of infected mice than LsAg. In contrast to these differences, active infection resulted in equivalent levels
of circulating GutAg-specific IgE and LsAg-specific IgE levels. Consistent with this, basophil activation, as
assessed by flow cytometric staining of intracellular basophil IL-4 expression, was equivalent in response
to GutAg and LsAg. Vaccination with GutAg adsorbed to CpG/alum induced GutAg specific IgG1 and
IgG2A production, with GutAg specific IgG titers greater than 5-fold higher than those measured in pre-
viously infected animals. Despite this response to GutAg vaccination, vaccinated mice harbored similar
parasite burdens 8 weeks post infection when compared to non-vaccinated controls. These studies dem-
onstrate that soluble antigens obtained from the intestinal tracts of L. sigmodontis have some qualities of
‘hidden’ antigens, but they still sensitize mice to allergic reactions and fail to protect against future infec-
tion when given as a vaccine adsorbed to alum/CPG.
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1. Introduction1
Filarial nematodes cause diseases such as African River Blind-
ness and Elephantiasis, debilitating conditions that have severe
economic, psychological, and social impacts on affected individuals
(Babu et al., 2002, 2006, 2009). Similarly, zoonotic nematodes such
as Dirofilaria immitis and Haemonchus contortus cause severe path-
ological sequelae in pets and livestock (Getachew et al., 2007;
McCall et al., 2008). While there are medications to treat these
infections, there are currently no vaccines to prevent them. Filarial
vaccines could provide a cost effective tool for aiding in the control
of these diseases.
Development of vaccines against parasitic filarial worms is
complicated by two major issues. The first challenge is the lack
of natural sterilizing immunity. In susceptible hosts, the immune
responses that develop during infection are generally inadequate
to clear the parasite. Indeed, filarial worms often survive for years
within permissive hosts despite the development of robust anti-
filarial immune responses (McCall et al., 2008). Furthermore, in
many models, these immune responses provide little or no protec-
tion against future infection (Denham et al., 1972, 1984; Klei et al.,
1990; Kowalski and Ash, 1975).
The second major challenge to filaria vaccine development is
the risk that vaccination would elicit allergic responses in exposed
individuals. Like other helminths, filariae typically induce a type 2
shifted immune response with production of high levels of parasite
specific IgE (Diemert et al., 2012; Maizels et al., 2004). Thus, a vac-
cine comprised of parasite antigen has the potential to induce
allergic reactions in individuals that are currently or have previ-
ously been infected with a filarial worm (Diemert et al., 2012).
The use of ‘‘hidden’’ antigens, antigens which are not typically
targeted by the immune system during the normal course of infec-
tion, could potentially overcome both of these obstacles. Interest-
ingly, prior studies have suggested that intestinal tracts of adult
nematodes may contain exactly such antigens. This concept has
been best demonstrated with Haemonchus contortus, a nematode
infection of sheep. Although infection elicits relatively low anti-
body levels to the intestinal tract of H. contortus, vaccination with
intestinal antigens induces substantial protection against chal-
lenge infection (Cachat et al., 2010; Smith, 1993). Antibodies from
vaccinated animals were shown to disrupt the parasite’s hemoglo-
binase activity, suggesting that protection occurs by inhibiting par-
asite metabolic activity (Ekoja and Smith, 2010). In addition to the
work carried out using fractions of intestinal antigens, vaccination
with individual digestive tract antigens has also shown protection
in many animal models of helminth infection (Acosta et al., 2008;
Chlichlia et al., 2001, 2003; Dalton et al., 2003; Loukas et al., 2004;
Pearson et al., 2009, 2010; Zhou et al., 2010).
In the field of filariasis, vaccination with intestinal antigens has
only been tried with the mouse model of D. immitis infection.
Although dogs infected with D. immitis were shown to produce
only low level antibody responses to D. immitis intestinal antigens,
presumably because these antigens are sequestered within the
worm (McGonigle et al., 2001), vaccination of mice with D. immitis
intestinal antigens induced high titer antibody responses to these
antigens and resulted in increased protection against challenge
infection (McGonigle et al., 2001). While exciting, this study was
limited by the use of D. immitis challenge into mice. D. immitis sur-
vives for only a short period of time in mice and has never been
shown to complete its lifecycle in this host (Abraham et al.,
1988; Zielke, 1977). For this reason, it is not clear if the protection
garnered through vaccination was simply the result of an acceler-
ated immune response to D. immitis, or if a truly novel protective
immune response was produced through vaccination.
The purpose of this study was to investigate the vaccine poten-
tial of filarial intestinal antigens using the permissive Litomosoides
sigmodontis BALB/c model of infection, the only murine model of
filariasis in which infective-stage L3 larvae develop into adults that
release microfilariae in fully immunocompetent mice (Hoffmann
et al., 2000). L. sigmodontis is a good model for investigating vac-
cine approaches for filariasis because the immune responses which
develop in infected mice closely mimic those observed in humans
(Babayan et al., 2003; Hoffmann et al., 2000; Taylor et al., 2005).
Additionally, enumeration of adult worms is reliably complete as
over 95% of the adult worms can be recovered from the pleural
cavity.
Specific goals of this study were to 1) determine the extent to
which intestinal antigens of L. sigmodontis (GutAg) are immunolog-
ically ‘‘hidden’’ during infection of mice, and 2) to test whether
vaccination with GutAg confers protection against challenge infec-
tion .
2. Materials and methods
2.1. Infection with L. sigmodontis
Infectious larvae of L. sigmodontis were obtained by performing
a pleural lavage on jirds 4 days after exposure to mites harboring
infectious stage larvae as previously described (Hubner et al.,
2009). Briefly, Jirds were euthanized with CO2, the peritoneal cav-
ity was opened, and a small incision (0.5 cm) made on the ventral
aspect of the diaphragm. A transfer pipette was used to flush the
pleural cavity repeatedly with 10 ml warmed (37 C) RPMI (Media-
tech Inc., Manassas, VA, USA). L3 larvae were then counted using a
dissecting microscope, aspirated with a 20 ll micropipettor, and
placed into a syringe. 40 L3 in 100 ll of RPMI were injected subcu-
taneously with a 22 gage needle into the nape of the neck of 5–
8 week old female BALB/c mice.
2.2. Production of soluble antigen extracts from whole worms (LsAg)
and worm intestines (GutAg)
Adult female worms were obtained from the pleural and perito-
neal cavities of infected jirds. These were separated and main-
tained in worm culture media until dissection, up to four days
using 12 well culture plates (5 worms in 3 ml/well). Worm culture
medium consisted of RPMI (Mediatech Cat 15-040-CV), 1% glucose
(Sigma–Aldrich Co. St. Louis, MO, USA), 100 I.U/ml Penicillin
(Mediatech Inc., USA), 100 lg/ml streptomycin (Mediatech Inc.,
USA), and 25 mM HEPES (Mediatech Inc., USA).
Worm dissections were carried out in PBS in a Petri dish using
fine tipped forceps and a dissecting microscope. Two sets of forceps
were used to grasp the cuticle. Pressure was applied in opposing
directions causing the cuticle to tear. The cuticle was then slowly
peeled away from the internal structures. The intestinal tract was
then separated from the two uterine tubes and placed in ice-cold
PBS. The intestines were stored at 20 C. Soluble GutAg (GutAg)
and soluble antigen from adult worms (LsAg) were prepared by
placing purified intestinal tracts or whole worms (male and fe-
male) into ‘‘D’’ tubes from BioPulverizer System 1 (MP Biomedicals
Cat 6750–200) and run on a FastPrep-24 system (MP Biomedicals)
at 4.0 M/s2 for 20 s. After mechanical homogenization, samples
were centrifuged at 16,100g for 1 min, supernatant saved, and
the pellet resuspended in another 1 ml PBS. The fast-prep run, cen-
trifugation, and removal of supernatant was repeated on the resus-
pended pellet. The saved supernatants were then combined,
centrifuged at 15,000g for 5 min, and the final supernatant re-
1 GutAg- Soluble fraction of antigens obtained from the digestive tract of adult L.
sigmodontisLsAg- Soluble fraction of antigens obtained from adult L. sigmodontisPI-
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trieved and saved as either GutAg or LsAg. Protein concentrations
were determined using the Pierce BCA Protein Assay Kit (Thermo
Scientific Rockford, IL, USA).
2.3. Timepoints of immune responses to GutAg and LsAg in infected
mice
As BALB/c mice clear adult worms by 20 weeks post infection
(PI), immune responses were evaluated at 8 and 22 weeks post
infection (PI) to determine antigen specific immune responses that
develop in currently infected and previously infected animals.
After CO2 euthanasia, blood was obtained from mice by cardiac
puncture, and plasma was obtained by separation with a plasma
separator tube (BD Cat #365958).
2.4. Measurement of GutAg- and LsAg-specific total IgG, IgG1, IgG2a,
and IgE antibodies
Prior to running IgE ELISAs, IgG antibodies were first adsorbed
from the plasma by overnight incubation with GammaBind Plus
Sepharose beads (GE Healthcare). Parasite specific antibody titers
were measured by ELISA in 96 well half area EIA/RIA plates (Corn-
ing #3690). Wells were coated overnight at 4 C with 50 ll of 2 lg/
ml of either LsAg or GutAg in PBS. Wells were washed in washing
buffer (PBS with 0.025% Tween 20 (Acros Organics) using an ELX
405 microplate washer (BioTek Instruments Winooski, VT, USA)
and subsequently blocked with 200 ll 5% BSA (Sigma–Aldrich),
0.05% Tween 20 (Acros Organics) in PBS at 37 C for two hours
and washed. Fifty microlitre of serially diluted plasma was added
and incubated overnight at 4 C. Fifty microlitre detection antibody
(purified goat anti mouse IgG conjugated to alkaline phosphatase
(Mabtech Cincinnati, OH Cat 3310-04)) diluted 1:1000, 2 lg/ml
biotinylated rat anti-mouse IgG1 (clone A85-1 BD Cat 50331),
2 lg/ml biotinylated rat anti mouse IgG2a (clone R19-15 BD Cat
550332), or 2 lg/ml biotinylated rat anti mouse IgE (Clone R35-
118 BD Cat 553419) was added and incubated 1 h at 37 C. Fifty
microlitre Streptavidin conjugated alkaline phosphatase (Jackson
Immunoresearch #016-050-084) diluted 1:1000 was then added
for IgE, IgG1 and IgG2a ELISAS and incubated 1 h at 37 C. 4-nitro-
phenyl phosphate disodium salt hexahydrate (Sigma–Aldrich
N9389) was then added at a concentration of 1 mg/ml in sodium
carbonate buffer (KD Medical Cat CUS-0242) and incubated for
35 min at room temperature. OD values were read at 405 nm with
a Victor3 microplate reader (Perkin Elmer). OD values of plasma
dilutions were graphed using graphpad, and a four parameter
curve was calculated for each mouse. This curve was used to deter-
mine the dilution of plasma from each mouse that would provide
an OD of twice background.
2.5. Splenocyte isolation
After C02 euthanasia of mice, spleens were removed, placed on a
70 lm nylon cell strainer (BD Falcon #352350) in a small petri dish
with 3 ml RPMI (Mediatech Inc) and crushed with a rubber tipped
plunger from a 3 ml syringe. Splenocytes were washed through the
cell strainer with 5 ml of RPMI. Cells were recovered and centri-
fuged at 400g for 10 min. Supernatant was removed and cells
were placed in 5 ml ACK lysing buffer (Quality Biological #118-
156-721) for 5 min. Ten microlitre of IgE media (Iscove’s DMEM
(Mediatech #15-016-CV) + 10% fetal calf serum (Valley Biomedical
#BS3032), 1% L-gutamine (Mediatech #25-005CI), 1% insulin-
transferrin-selenium (Mediatech #25-800-CR), and 80 ug/ml Gen-
tamicin (Quality Biological #120-098-661)) was added and the
cells were centrifuged again at 400g for 10 min. Supernatant
was removed and the cells were resuspended in 10 ml IgE Media.
The number of splenocytes was determined by using a Countess
automated cell counter system (Invitrogen C10227). Cells were
then diluted with IgE media to a concentration of 2  106 cells/ml.
2.6. Cytokine assays
2  106 splenocytes were cultured in 1 ml aliquots in a 48 well
plate at 37 C for 3 days stimulated with either media, 15 lg
GutAg, or 15 lg LsAg. After 72 h, plates were centrifuged at
400g for 10 min and the supernatant was carefully removed
and placed in microtiter tubes. These were centrifuged again at
400g for 10 min to remove any residual splenocytes. The super-
natant was saved and stored at 20 C. Levels of IL-4, IL-10 and
IFN-gamma were obtained with the eBioscience, READY SET GO
ELISAS (Cat #88-7044-88, #88-7104-88, #88-7314-88) according
to their included protocols.
2.7. Proliferation assay
200,000 splenocytes were cultured in a 100 ll aliquots in a 96
well plate at 37 C for 72 h. Splenocytes were stimulated with
either media, 15 lg/ml GutAg or 15 lg/ml LsAg. Cell proliferation
was determined using a BRDU Chemiluminescence assay (Roche
#11 669 915 001) according to the manufacturer’s protocol. BRDU
was diluted 1:100 with IgE media to make the BRDU labeling solu-
tion. Ten microlitre of BRDU labeling solution was added 72 h after
stimulation of splenocytes, and the splenocytes were incubated at
37 C for 17 more hours. Cells were centrifuged at 300g for
10 min, and the supernatant was removed. A hair dryer was used
to completely dry the plates containing splenocytes. Two hundred
microlitre of FixDenat solution was added to each well for 30 min
at room temperature. One hundred microlitre anti-BRDU peroxi-
dase (POD) working solution was then added to each well, and
plates were incubated for 90 min at room temperature. Wells were
then washed three times with 200 ll of the included washing buf-
fer with a soaking time of 1 min each. Finally, 100 ll of substrate
solution was added and plates were shaken for 3 min. Lumines-
cence was read with a Victor3 microplate reader (Perkin Elmer).
Proliferation indexes were obtained by dividing the luminescence
of antigen stimulated wells by those of the media stimulated wells.
2.8. Basophil stimulation
8 week infected BALB/c mice were euthanized with CO2. Blood
was obtained by cardiac puncture with a 22 gage needle, placed
in heparanized tubes (Sarstedt #41.1503.105) and centrifuged at
400g for 10 min. Plasma was removed and cells were washed
with RPMI, centrifuged again, and resuspended in a volume of
RPMI that corresponded with the amount of plasma removed. Cells
were then divided into 100 ll aliquots and stimulated with addi-
tion of 100 ll RPMI alone as a control or with 100 ll of 4 lg/ml
of GutAg or LsAg in RPMI to obtain final concentrations of 2 lg/
ml. Samples were incubated at 37 C in 5% CO2. GolgiStop (BD)
was added at a final concentration of 0.7 ll/ml after 1 h and cells
were then incubated for an additional 2 h. Cells were then washed
with PBS and centrifuged at 500g for 8 min. Red blood cells were
lysed and the remaining cells fixed with a whole blood lysing re-
agent kit (Beckman Coulter). Cells were washed twice with 2 ml
PBS and blocked overnight at 4 C with 1%BSA/PBS. Cells were
stained with anti-IgE FITC (BD Clone R35-72), anti-CD4 PerCP
(BD clone RM4-5)), anti-CD45b/B220 PerCP (BD clone RA3-6B2),
and incubated at 4 C for 30 min. Cells were then permeabilized
with 2 ml permeabilization/wash buffer (BD) for 15 min at room
temperature in the dark. Cells were centrifuged as before, resus-
pended in 100 ll BD Perm/wash buffer, and stained with anti-IL-
4 APC (BD Clone 11B11) for 30 min at 4 C in the dark. Cells were
washed twice more with PBS and resuspended in 200 ll PBS and
C.P. Morris et al. / Experimental Parasitology 135 (2013) 87–95 89
analyzed on an LSR II flow cytometer (BD). Analysis was conducted
using BD FacsDiva software. Basophils were identified as IgE high
and CD4/B220 low cells. All flow cytometry antibodies were ti-
trated prior to use. Cut-offs for determination of activated baso-
phils on the basis of IL-4 positivity were determined using a
fluorescence minus one control.
2.9. Vaccination
GutAg was mixed with CpG (30 BP Thioate), Alum (Thermosci-
entific), and PBS to create a mixture containing 10 lg of GutAg,
25 ug CpG, 25 lg alum (.64 ll) per 100 ll of fluid. This mixture
was shaken at room temperature for 30 min. One hundred micro-
litre (10 lg of antigen) was injected IP into female BALB/c mice for
a total of 3 times at 3 week intervals. Control mice received similar
injections of PBS with the same concentration of CpG and Alum,
but without antigen. Two hundred microlitre of blood was drawn
retro-orbitally 2 weeks after each injection for determination of
parasite specific antibody levels. Mice were infected with 40 L3s
subcutaneously 3 weeks after their last vaccination.
2.10. Determination of microfilaria levels and adult worm numbers
8 weeks post infection, mice were euthanized with CO2. Blood
was drawn via cardiac puncture with a 22 gage needle. Thirty
microlitre of blood was then transferred into 1 ml of ACK lysing
Buffer (Quality Biological Gaithersburg, MD, USA) and stored at
room temperature for 1–3 days for microfilarial counts. This was
centrifuged at 400g for 10 min, and the supernatant aspirated un-
til about 50 ll remained. The pellet was resuspended in the
remaining volume and then placed onto a slide and covered with
a cover slip. All microfilariae on the slide were counted.
After cardiac puncture, the peritoneal cavity was opened and all
aspects of it visually inspected for adult worms with use of a dis-
secting probe. A small incision was then made in the ventral aspect
of the diaphragm and a large tip transfer pipette was used to lavage
the pleural cavity with 10 ml warmed RPMI (Mediatech Inc., USA).
The fluid and worms obtained from the lavage were transferred to
a petri dish. After lavage, the diaphragm was cut away and in-
spected for adult worms along with the rest of the pleural cavity.
All remaining adult worms that were found were transferred to a
Petri dish using a dissecting probe. Worms were separated using
fine tipped forceps, sexed, and counted with the aid of a dissecting
microscope.
2.11. Animal use
Mice were housed at the Uniformed Services University of the
Health Sciences (USUHS) laboratory animal facility and had access
to food and water ad libitum. All research was conducted under
protocols approved by the USUHS Institutional Animal Care and
Use Committee.
2.12. Statistical analysis
Immune responses to GutAg and LsAg in the same mice were
compared using the non-parametric Wilcoxon Matched Pairs test.
The non-paired, non-parametric Mann–Whitney test was used for
immunological and worm burden comparisons between vacci-
nated and unvaccinated mice. All analyses were conducted using
GraphPad Prism software (GraphPad, LaJolla).
3. Results
3.1. Microdissection enables purification of L. sigmodontis intestinal
tracts
To determine whether dissection of adult female L. sigmodontis
results in pure preparations of filarial intestines, components of
worms obtained during dissection were stained with hematoxylin
and eosin and evaluated histologically. As seen in Fig. 1, microdis-
section enables purification of intestinal tracts from adult female L.
sigmodontis worms.
Fig. 1. Gross anatomy and histology of adult female Litomosoides sigmodontis. Gross anatomy as seen from the dissecting scope prior to (A) and after (B) mechanical rupture of
the cuticle (25). Longitudinal (C) and Cross sectional (D) views of adult female worm prior to dissection (H&E, 400). (E) Purified intestinal tract from adult female worm
with characteristic single layer of cuboidal cells. The intestinal tract is viewed after purification repeatedly folded back on itself (H&E, 400). (Black arrow = Intestinal tract,
Asterisk = Uterine Tube, Blue triangle = Cuticle). (For interpretation of color in this Figure, the reader is referred to the web version of this article).
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3.2. Infected mice display lower immune responses to GutAg than to
LsAg
To determine the extent to which intestinal antigens are ‘‘hid-
den’’ from the immune system during L. sigmodontis infection, hu-
moral and cellular responses toward parasite antigens were
measured in mice with active infections (8 weeks PI) and previous
infections (22 weeks PI). IgG antibody titers to either the soluble
fraction of the entire worm (LsAg), or the soluble fraction of the
worm digestive tract (GutAg) were determined by ELISA. Origi-
nally, we hypothesized that currently infected mice would display
relatively weak adaptive immune responses to GutAg compared to
LsAg because of sequestration of these antigens from the host im-
mune system. We also hypothesized that 22 weeks PI, after worm
death and degradation had occurred, that these titers would in-
crease as the immune system may have had an opportunity to
interact with antigens from the worm digestive tracts. However,
we found that GutAg specific immune responses were low both
during and after infection (Fig. 2).
As seen in Fig. 2A, mice developed high titers of LsAg specific
IgG antibodies during active infection which dropped after worm
clearance had occurred. At both time points, these titers were sig-
nificantly greater than GutAg specific IgG titers. In contrast to IgG,
LsAg and GutAg IgE titers were similar during active infection. In
previously infected mice, however, GutAg-specific IgE titers were
significantly lower than those against LsAg (Fig. 2B).
Cellular responses were also generally lower against GutAg than
LsAg. At both time points evaluated, splenocyte proliferation and
production of IL-4 and IFN-cwere lower in response to GutAg than
to LsAg (Fig. 3A–C). No differences were observed with respect to
splenocyte IL-10 production (Fig. 3D).
3.3. GutAg induces basophil activation in L. sigmodontis-infected mice
To assess the allergic potential of GutAg, we assessed the extent
to which GutAg activates basophils during infection. As basophils
are allergy effector cells that are activated by cross-linking of sur-
face-bound IgE antibodies, basophil activation tests are immuno-
logical markers for allergic responses (Hausmann et al., 2009). To
measure basophil activation, peripheral blood cells were obtained
from 8 week infected mice, stimulated with either GutAg or LsAg,
and then evaluated for the production of IL-4 by flow cytometry.
As seen in Fig. 4, GutAg stimulation induced equivalent activation
of basophils as LsAg (mean % IL-4 + basophils = 33% after media
stimulation vs. 60% after both GutAg and LsAg stimulation). This
result, along with the development of GutAg-specific IgE antibod-
ies, suggests that vaccination with the soluble fraction of filarial
intestinal antigens may not circumvent the issue of allergic re-
sponses in exposed individuals.
3.4. Vaccination results in increased anti-Gut IgG production, and
balanced IgG1/IgG2A responses
Since antibody responses to GutAg remained fairly low
throughout infection, we tested whether vaccination with GutAg
could induce robust anti-GutAg antibody production. Because prior
filaria vaccine studies have shown that both type 1 and type 2
responses can have protective effects against filaria infection
(Abraham et al., 2001; Hartmann et al., 2006), we chose to use a
combination of CpG and Alum as adjuvants to induce a broad-
based immune response. As seen in Fig. 5A, mice vaccinated three
times with 10 lg GutAg developed anti-GutAg IgG titers over five
fold higher than previously infected mice. Furthermore, vaccinated
mice produced a more balanced ratio of IgG subtypes, including
both IgG1 and IgG2A. Conversely, previously infected mice
produced almost exclusively the TH2-associated IgG1 subtype
which provides very little complement fixation (Klaus et al.,
1979; Neuberger and Rajewsky, 1981) (Fig. 5B).
3.5. Vaccination with gut antigen fails to protect against challenge
infection
In order to determine the efficacy of a vaccine comprised of
GutAg, mice were vaccinated three times with either GutAg ad-
sorbed to CPG/alum or saline with CpG/alum. Three weeks after
the last vaccination, mice were infected with 40 infectious larvae.
Eight weeks after infection, adult and microfilaria parasite burdens
were determined. No protection was garnered from vaccination
with GutAg, as vaccinated mice harbored 19.4 worms on average,
whereas non-vaccinated mice only harbored an average of 18.3
worms (Fig. 6A). Microfilaria burdens in vaccinated animals were
also similar to those of non-vaccinated animals (Fig. 6B).
4. Discussion
Filarial worms cause diverse and debilitating diseases through-
out much of the tropics, and a vaccine would aid in both control
and possible elimination of these diseases. Vaccine development
in filariasis is complicated by a lack of protective immunity during
infection and by possible allergic responses to worm antigens after
exposure (Denham et al., 1972, 1984; Diemert et al., 2012; Klei
et al., 1990; Kowalski and Ash, 1975). Because the digestive tract
is sequestered within the worm, and thus may be immunologically
‘‘hidden’’ during the course of normal infection, vaccination against
intestinal antigens has been proposed as a possible means of
Fig. 2. Antibody titers to soluble antigens prepared from entire L. sigmodontis worms (LsAg) or their digestive tracts (GutAg) in currently infected (8 week) or previously
infected (22 week) BALB/c mice. Shown are composite results from two independent experiments, each of which had 5 animals per group. (⁄ = p < 0.05, ⁄⁄ = p < 0.01,
⁄⁄⁄ = p < 0.001).
C.P. Morris et al. / Experimental Parasitology 135 (2013) 87–95 91
overcoming these obstacles (Getachew et al., 2007; Hotez et al.,
2010; McGonigle et al., 2001).
Studies using the nematode models of Haemonchus and Dirofil-
aria have shown that infection elicits weak antibody responses to
parasite intestinal antigens and that vaccination with intestinal
antigens induces high antibody responses and protection against
infection (McGonigle et al., 2001; Smith, 1993). However, neither
of the models used to date have been ideal vaccine models for hu-
man filariasis. Haemonchus is a non-filarial nematode parasite of
the intestinal tract, and the Dirofilaria experiments utilized a
non-permissive host to determine vaccine efficacy. Thus, in this
study we used the permissive L. sigmodontis BALB/c model of fila-
riasis to investigate the vaccine potential of filarial intestinal
antigens.
Our studies demonstrate that infection, despite inducing lower
IgG and cellular responses to GutAg, results in allergic sensitization
against filaria intestinal antigens. Further, vaccination with these
intestinal antigens fails to protect against challenge infection de-
spite the development of high GutAg-specific antibody titers.
Our first set of experiments evaluated the immunological re-
sponses to GutAg in actively infected and previously exposed mice
to determine the extent to which intestinal antigens are immuno-
logically ‘hidden’ during infection. Similar to other models, the IgG
responses that developed to GutAg were relatively low. Further-
more, while splenocytes of infected mice responded to GutAg,
cytokine production and proliferation of splenocytes were gener-
ally lower to these antigens than to LsAg. Overall, the lower hu-
moral and cytokine responses to GutAg when compared to LsAg
suggest that a large portion of the antigens contained within the
digestive tract of the worm may remain hidden from the immune
system throughout infection. It is important to note, though, that
the lower antibody and cellular immune responses observed to-
wards GutAg may have also been due to a quantitative phenome-
non whereby the more antigenically diverse LsAg induced greater
immune responses than GutAg because of a higher number of dis-
tinct antigens present in the mixture.
In terms of allergic sensitization, our study clearly shows that
GutAg is not immunologically hidden. Both actively infected and
previously infected mice produce GutAg-specific IgE. This IgE is
functional, as basophil activation assays demonstrated that GutAg
was as effective as LsAg in activating basophils of infected mice.
These results suggest that even though infection results in lower
cellular and IgG responses to GutAg than to LsAg, prior infection
still results in allergic sensitization to at least some intestinal anti-
gens. Consequently, future studies investigating vaccine potential
of individual intestinal antigens will have to ensure prior infection
does not result in allergic sensitization to those antigens.
Vaccination of mice with GutAg adsorbed to CpG and Alum re-
sulted in high titers of GutAg-specific IgG1 and IgG2a antibodies.
Despite this, GutAg vaccination failed to protect against infection.
This either occurred because the titer of antibodies induced was
not high enough to enable protection, or because GutAg specific
antibodies simply do not have the capability to protect against
infection in this model. One can speculate that GutAg specific anti-
bodies are unable to interact with their specific antigens in this
model because of either a lack of antibody ingestion by the parasite
or because antibodies are degraded by proteases within the worm
digestive tract.
Despite the negative results of this study, we suspect that some
intestinal tract antigens do have the potential to function as effec-
tive filaria vaccine candidates. First, there is direct evidence that
some antigens present in the intestinal tracts of filariae can serve
as effective vaccine candidates. Preliminary evidence from a pro-
teomic study we are conducting demonstrates that glutathione-
S-transferase and thioredoxin peroxidase are present within the
digestive tract of filarial worms. As both of these antigens induce
protection when used to vaccinate jirds against filariasis (Dabir
et al., 2008; Rathaur et al., 2008; Vanam et al., 2009), it is clear that
some antigens located in filarial intestinal tracts can function as
effective vaccine antigens. Second, it is unlikely that the lack of
protection in this model is due to a lack of worm antibody inges-
tion as L. sigmodontis worms ingest blood between 28 and 56 days
Fig. 3. Splenocyte responses in 8 week and 22 week infected BALB/c mice when cultured for 3 days at 2 million cells/ml and stimulated with 15 lg/ml LsAg or GutAg. (A)
Splenocyte proliferation as measured by incorporation of BRDU. (B–D) Cytokine levels in the supernatant of splenocytes as measured by ELISA. Shown are composite results
from two independent experiments, each of which had 5 animals per group. (⁄ = p < 0.05, ⁄⁄ = p < 0.01).
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PI (Attout et al., 2005), providing some opportunity for antibody
ingestion. It is also likely that L. sigmodontis ingests antibodies di-
rectly from the pleural fluid. Thus, the most likely reason for the
lack of protection observed in this study is that no protective anti-
gen within the intestinal fraction was given in a high enough dose
to elicit a protective immune response.
Proof of concept demonstrating that individual antigens can
function as protective vaccines, even when a mixture of antigens
does not, has been shown with adult filarial worm antigens. In per-
missive rodent models, vaccination with soluble extracts of adult
filarial worms generally does not confer substantial protection.
Vaccination of jirds with the soluble fraction of adult Brugia pahan-
gi does not elicit any significant decrease in adult worm burden,
and vaccination with Brugia malayi adult somatic antigen confers
only 25% protection against challenge infection (Klei et al., 1982;
Vedi et al., 2008). While there are no published reports on the
Fig. 4. Basophil responses to LsAg or GutAg in 8 week infected mice. (A) Cells were initially gated by forward and side scatter characteristics (left panel). Basophils were
identified by high expression of IgE and low expression of CD4 and B220 (Mid Panel). IL-4 expression in unstimulated (right top) and stimulated basophils (right bottom). (B)
Percentages of basophils positive for IL-4 after stimulation with 2 lg/ml LsAg or GutAg. Shown are composite results from two independent experiments, one which had 4
animals per group and one which had 5 animals per group.
Fig. 5. Anti-GutAg antibody titers in 22 week infected mice and mice vaccinated with GutAg + CpG/Alum as measured by ELISA. (A) Total anti-GutAg IgG titers. (B) IgG1 and
IgG2A titers. Shown are composite results from two independent experiments, each of which had 4–5 animals per group. (⁄⁄⁄ = p < 0.001).
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use of LsAg as a vaccine in mice, vaccination of albino rats with
LsAg results in no protection against infective larvae or adult stages
(Mehta et al., 1981). Despite the lack of efficacy of adult worm anti-
gen extracts, effective vaccination with specific antigens contained
in these mixtures has been demonstrated numerous times (Baba-
yan et al., 2012; Li et al., 1993; Vanam et al., 2009; Vedi et al.,
2008; Veerapathran et al., 2009). Consequently, the negative re-
sults of this study do not rule out the possibility that specific intes-
tinal antigens may be able to confer substantial protection even
though a homogenate of intestinal antigens does not.
In conclusion, in this study we demonstrated that the soluble
fraction of filarial intestinal antigens elicits allergic sensitization
during infection and fails to protect when used as a vaccine ad-
sorbed to alum and CpG. While disappointing in terms of filaria
vaccine development, these findings do not rule out the possible
existence of individual intestinal antigens that could be both pro-
tective and safe. One of the major limitations of this study was
obtaining enough GutAg for all of the studies involved. Indeed, it
took a single investigator (C.P.M.) more than 350 h to dissect the
3000+ worms used to obtain enough purified filarial intestinal
tracts for the experiments done in this study. As such, increasing
the concentrations of GutAg used for vaccination or testing various
fractions of GutAg are likely not feasible approaches for further
investigating the potential of filarial intestinal antigens as vaccine
candidates. Consequently, we are currently conducting a proteo-
mic analysis to identify antigens present only within the intestines
of filarial worms. Recombinant expression of such antigens or use
of DNA vaccines can then be tried in future studies to explore the
potential of specific intestinal antigens to function as effective vac-
cine candidates.
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